nach oben

Drugs

Erschienen in:

01.08.2016 | AdisInsight Report

Atezolizumab: First Global Approval

verfasst von: Anthony Markham

Erschienen in: Drugs | Ausgabe 12/2016

Einloggen, um Zugang zu erhalten

Abstract

Atezolizumab (Tecentriq™)—a monoclonal antibody targeting programmed death ligand 1 (PD-L1 or CD274 antigen)—is being developed by Genentech as treatment for a variety of haematological malignancies and solid tumours. It been approved in the US as a second-line therapy for urothelial carcinoma and is awaiting approval as a second-line therapy for non-small cell lung cancer. This article summarizes the milestones in the development of atezolizumab leading to this first approval for urothelial carcinoma.

FDA. FDA approves new, targeted treatment for bladder cancer [media release]. 6 Jun 2016. http://www.fda.gov.

Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–7.CrossRefPubMedPubMedCentral

Genentech Inc. Prescribing information for Tecentriq™ (atezolizumab) injection, for intravenous use. 2016. http://www.gene.com/download/pdf/tecentriq_prescribing.pdf. Accessed 20 May 2016.

Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet. 2016;387(10031):1909–20.CrossRefPubMed

Petrylak DP, Powles T, Bellmunt J, et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC) [abstract no. 4501]. J Clin Oncol. 2015;33(Suppl).

Fehrenbacher L, Spira A, Ballinger M, et al. Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial. Lancet. 2016;387(10030):1837–46.CrossRefPubMed

Besse B, Johnson M, Janne PA, et al. Phase II, single-arm trial (BIRCH) of atezolizumab as first-line or subsequent therapy for locally advanced or metastatic PD-L1-selected non-small cell lung cancer (NSCLC) [abstract no. 16LBA]. Eur J Cancer. 2015;51(Suppl 3):S717–8.CrossRef

Spigel DR, Chaft JE, Gettinger SN, et al. Clinical activity and safety from a phase II study (FIR) of MPDL3280A (anti-PDL1) in PD-L1-selected patients with non-small cell lung cancer (NSCLC) [abstract no. 8028]. J Clin Oncol. 2015;33(Suppl).

Camidge R, Liu SV, Powderly J, et al. Atezolizumab (MPDL3280A) combined with platinum-based chemotherapy in non-small cell Lung cancer (NSCLC): a phase Ib safety and efficacy update [abstract no. ORAL02.07]. J Thorac Oncol. 2015;10(9 Suppl 2):S176–7.

10.

Emens LA, Braiteh FS, Cassier P, et al. Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC) [abstract no. 2859]. Cancer Res. 2015;75(15 Suppl).

11.

Adams S, Diamond J, Hamilton E, et al. Safety and clinical activity of atezolizumab (anti-PDL1) in combination with nab-paclitaxel in patients with metastatic triple-negative breast cancer [abstract no. P2-11-06]. Cancer Res. 2016;76(4 Suppl).

12.

McDermott DF, Sosman JA, Sznol M, et al. Atezolizumab, an anti-programmed death-ligand 1 antibody, in metastatic renal cell carcinoma: long-term safety, clinical activity, and immune correlates from a phase Ia study. J Clin Oncol. 2016;10(34):833–42.CrossRef

13.

Sznol M, McDermott DF, Jones SF, et al. Phase Ib evaluation of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) in patients (pts) with metastatic renal cell carcinoma (mRCC) [abstract no. 410]. J Clin Oncol. 2015;33(Suppl 7).

14.

Bendell J, Kim TW, Goh BC, et al. Clinical activity and safety of cobimetinib (cobi) and atezolizumab in colorectal cancer (CRC) [abstract no. 3502]. J Clin Oncol. 2016;34(Suppl).

15.

Boyd Z, Smith D, Baker B, et al. Development of a PD-L1 companion diagnostic IHC assay (SP142) for atezolizumab [abstract no. B001]. Cancer Immunol Res. 2016;4(Suppl).

16.

Castellano D, Albers P, Gschwend JE, et al. A phase III study of the efficacy and safety of adjuvant atezolizumab (anti-PDL1) vs observation in patients with muscle-invasive urothelial carcinoma of the bladder (IMvigor 010) [abstract]. Eur Urol. 2016;15(3 Suppl).

17.

Herbst RS, De Marinis F, Jassem J, et al. Phase III clinical trials of atezolizumab compared with standard chemotherapy in PD-L1-selected chemotherapy-naive patients with advanced NSCLC [abstract no. 355TiP]. Ann Oncol. 2015;26(Suppl 9):i105–6.

18.

Mok TSK, Cappuzzo F, Jotte RM, et al. Phase III clinical trials of atezolizumab in combination with chemotherapy in chemotherapy-naive patients with advanced NSCLC [abstract no. 356TiP]. Ann Oncol. 2015;26(Suppl 9):ix106.CrossRef

19.

Rizvi NA, Chow LQM, Dirix LY, et al. Clinical trials of MPDL3280A (anti-PDL1) in patients (pts) with non-small cell lung cancer (NSCLC) [abstract no. TPS8123]. J Clin Oncol. 2014;32(5 Suppl).

20.

Emens L, Adams S, Loi S, et al. A phase III randomized trial of atezolizumab in combination with nab- paclitaxel as first line therapy for patients with metastatic triple-negative breast cancer (mTNBC) [abstract no. OT1-01-06]. Cancer Res. 2015;76(4 Suppl).

Titel: Atezolizumab: First Global Approval
verfasst von: Anthony Markham
Publikationsdatum: 01.08.2016
Verlag: Springer International Publishing
Erschienen in: Drugs / Ausgabe 12/2016
Print ISSN: 0012-6667
Elektronische ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-016-0618-8

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2016

Unmet Needs in LDL-C Lowering: When Statins Won’t Do!

Obeticholic Acid: First Global Approval

Diclofenac Sodium Bolus Injection (DylojectTM): A Review in Acute Pain Management

Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients

Lumacaftor/Ivacaftor: A Review in Cystic Fibrosis

Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection